SGLT2i, beta blocker, ARNI, MRA, MTD

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Heart Failure

Conditions

Heart Failure

Trial Timeline

May 5, 2023 → Jun 9, 2025

NCT ID

NCT05734690

About SGLT2i, beta blocker, ARNI, MRA, MTD

SGLT2i, beta blocker, ARNI, MRA, MTD is a approved stage product being developed by Eli Lilly for Heart Failure. The current trial status is completed. This product is registered under clinical trial identifier NCT05734690. Target conditions include Heart Failure.

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure were approved

Approved (20) Terminated (3) Active (0)

✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved

✅ConivaptanAstellas PharmaApproved

✅RegadenosonAstellas PharmaApproved

✅Regadenoson + GadoliniumAstellas PharmaApproved

✅regadenosonAstellas PharmaApproved

✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

✅Dapagliflozin 10mg TabAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05734690	Approved	Completed	May 5, 2023	Jun 9, 2025	Heart Failure

Competing Products

20 competing products in Heart Failure

See all competitors

Product	Company	Stage	Hype Score
mRNA-0184	Moderna	Phase 1	0
IV diuretic	Nuwellis	Pre-clinical	16
IV Loop Diuretics	Nuwellis	Pre-clinical	23
Stepped pharmacologic care	Nuwellis	Phase 3	30
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	8
TRV120027 + Normal Saline	Trevena	Phase 1	19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	25
TRV120027 + Placebo	Trevena	Phase 1/2	22
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	25
INXN-4001	Precigen	Phase 1	23
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	32
Olmesartan	Daiichi Sankyo	Phase 3	40
Carperitide + Placebo	Daiichi Sankyo	Phase 2	35
Edoxaban	Daiichi Sankyo	Pre-clinical	22
Regadenoson	Astellas Pharma	Phase 1	29
Advagraf + Prograf	Astellas Pharma	Phase 2	35
FK506E	Astellas Pharma	Phase 3	40